1Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran
2Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
3Reproductive Biotechnology Research Centre, Avicenna Research Institute (ACECR), Tehran AND Department of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran
4Department of Epidemiology and Biostatics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
5Department of Community Medicine, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
We aimed to evaluate the safety and efficacy of ANGIPARS™ in a phase 2 clinical trial. This study was performed as a phase 2 clinical trial without a control group between May 2007 and September 2008 in the Iranian Rheumatology Research Center on a group of volunteer patients that were diagnosed with scleroderma. Patients with the diagnosis of diffuse or limited scleroderma without the involvement ofinternal organs were given 100 mg ANGIPARSTM capsules three times a day for 6 months, followed by 2 capsules a day for a further 3 months. Follow-up continued for a year. At the baseline, modified Rodnan score, pain severity and number of pitting ulcers, number of perioral folds, finger to palm distance, and open- mouth area were assessed in each patient. The measurements were repeated on a monthly basis and their change from the baseline was calculated. Possible adverse effects were monitored at regular monthly intervals through a complete set of laboratory tests and clinical examination. Eleven patients including 10 females were recruited. The mean age was 39 years (SD = 10.2). No significant changes and no abnormality in laboratory measures were found during the study. Repeated measure analysis revealed a significant reduction in the modified Rodnan score (Mean reduction= 38%, P value < 0.001), finger to palm distance and number of pitting ulcers (mean reduction 33% & 87.5%, respectively, and P values < 0.001 & 0.003, respectively), and an increase in open-mouth area (mean reduction = 20.6%, P value = 0.041). The drug had no effect the pain of the ulcers or on the perioral folds. ANGIPARSTM is efficient and safe for the treatment of the skin manifestations of scleroderma. Conducting a phase III placebo controlled randomized trial is recommended.
Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008; 66:198-202.
Alivernini S, De Santis M, Tolusso B, Mannocci A, Bosello SL, Peluso G, Pinnelli M, D'Antona G,LaTorre G, Ferraccioli G. Skin ulcers in systemic sclerosis:determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009; 60:426-435.
Wigley FM, Flavahan NA. Raynaud's phenomenon.Rheum Dis Clin North Am 1996; 22:765-781.
Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139-153.
Mawdsley AH. Patient perception of UK scleroderma services--results of an anonymous questionnaire. Rheumatology (Oxford) 2006; 45:1573.
Gliddon AE, Dore CJ, Maddison PJ. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006;55:473-479.
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985-3993.
Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. High-dose versus low-dose D- penicillamine in early diffuse systemic sclerosis: analysis of a two-year,double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42:1194-1203.
Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 2008;158:1063-1068.
Chamaillard M, Heliot-Hosten I, Constans J, Taïeb A.Bosentan as a rescue therapy in scleroderma refractory digital ulcers. Arch Dermatol 2007; 143:125-126.
Selenko-Gebauer N, Duschek N, Minimair G, Stingl G and Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2006; 45 Suppl 3:iii45-48.
Garcia de la Pena-Lefebvre P, Rodriguez Rubio S, Valero Exposito M, Carmona L, Gámir Gámir ML, Beltrán Gutiérrez J, Díaz-Miguel C, Orte Martínez J and Zea Mendoza A C. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008; 47: 464-466.
Snyder MJ, Jacobs MR, Grau RG, Wilkes DS, Knox KS.Resolution of severe digital ulceration during a course of Bosentan therapy. Ann Intern Med 2005; 142:802-803.
Abdollahi M, Farzamfar B, Salari P, Khorram Khorshid
R, Larijani B, Farhadi M, Madani SH. Evaluation ofacute and sub-chronic toxicity of Semelil (ANGIPARS), a new phytotherapeutic drug for wound healing in rodents. Daru 2008; 16:7-14.
Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky YA and Farhadi M. Sub- chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. Daru 2008; 16:15-19.
Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salari P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS). Daru 2008; 16:20-24.
Masoompour SM, Bagheri MH, Borhani Haghighi A,Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS, a new herbal drug on diabetic foot ulcer: A phase 2 clinical study. Daru 2008; 16:31-34.
Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K,Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M, Gharibdoust F, Madani SH. Effects of intravenous Semelil (ANGIPARS) on diabetic foot ulcers healing: A multicenter clinical trial. Daru 2008; 16:35-40.
Bahrami A, Kamali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorshid HR,Gharibdoust F, Madani SH, Larijani B. Clinical application of oral form of ANGIPARS and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial. Daru 2008; 16:41-48.
Heshmat R, Mohammad K, Mohajeri Tehrani MR,Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARS) in patients with diabetic foot ulcer: A Phase I clinical trial. Daru 2008;16:25-30.
Shamimi Nouri K, Karimian R, Nasli E, Kamali K, Chaman R, Farhadi M, Madani SH, Larijani B, Khorram Khorshid HR. Topical application of Semelil(ANGIPARS) in treatment of pressure ulcers: A randomized clinical trial. Daru 2008; 16:54-57.
Shamimi Nouri K, Heshmat R, Karimian R, Nasli E, Larijani B, Novitsky YA, Farhadi M, Gharibdoust F.Intravenous Semelil (ANGIPARS) as a novel therapy for pressure ulcers: A randomized clinical trial. Daru 2008;16:49-53.
Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, Sheeran T, Stevens C, Wollheim F.Reliability of skin involvement measures in scleroderma.The UK Scleroderma Study Group. Br J Rheumatol 1992; 31:457-460.
Understanding Clinical Trials: The U.S. National Institute of Health, 2009.
Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D,Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44:1351-1358.
Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol 2009; 160:1075-82.
Funauchi M, Kishimoto K, Shimazu H, Nagare Y, Hino S, Yano T, Kinoshita K. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int 2009; 29:769-775.
Dharmananda S. TREATING SCLERODERMA WITH CHINESE HERBS.
Gaby AR. Natural remedies for scleroderma. Altern Med Rev 2006; 11:188-195.
Jablonska S. Avocado/soybean unsaponifiables in the treatment of scleroderma: comment on the article by Maheu et al. Arthritis Rheum 1998; 41:1705.
Stainforth JM, Layton AM, Goodfield MJ. Clinical aspects of the use of gamma linolenic acid in systemic sclerosis. Acta Derm Venereol 1996 ;76: 144-146.
Belch JJ, Shaw B, O'Dowd A, Saniabadi A, Leiberman P, Sturrock RD, Forbes CD. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost 1985; 54: 490-494.
Hachulla E, Clerson P, Launay D, Lambert M, Morell- Dubois S, Queyrel V, Hatron PY. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-2430.
Czirjak L, Foeldvari I, Muller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxford) 2008; 47: v44-45.
Gärtner R, Gasnier BC, Dietrich JW, Krebs B,Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 2002;87:1687- 1691.
Köhrl J, Brigelius-Flohé R, Böck A, Gärtner R, Meyer O, Flohé L. Selenium in biology: facts and medical perspectives. Biol Chem 2000; 381:849-864.
McKenzie RC, Rafferty TS, Beckett GJ. Selenium: an essential element for immune function. Immunol Today 1998; 19:342-345.